CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliance Certificate Pursuant To Regulation 7(3) Of Securities Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended 31St March, 2023.
Please find enclosed compliance certificate for the financial year ended 31st March, 2023 pursuant to Regulation 7(3) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, for your reference and records. CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate for the quarter ended March 31, 2023 issued by Company''s Registrar and Share Transfer Agent (RTA), i.e. M/s. Purva Sharegistry (India) Private Limited thereby confirming the compliances under the said regulation. CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issue of Duplicate Share Certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure requirement), Regulation, 2015 CHEMO PHARMA LABORATORIES LTD. - 506365 - Closure of Trading Window
Intimation of Trading Window Closure CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issue of Duplicate Share Certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure requirement), Regulation, 2015 CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issue of Duplicate Share Certificate under Regulation 39(3) of SEBI (Listing Obligation and Disclosure requirement), Regulation, 2015 CHEMO PHARMA LABORATORIES LTD. - 506365 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of the newspaper advertisement pertaining to financial results of the Company for the quarter and nine months ended December 31, 2022. CHEMO PHARMA LABORATORIES LTD. - 506365 - Outcome Of Board Meeting Held On Tuesday, January 31, 2023
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. January 31, 2023, approved the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review Report thereon. CHEMO PHARMA LABORATORIES LTD. - 506365 - Board Meeting Outcome for Un-Audited Financial Results Held On Tuesday, January 31, 2023
Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), we wish to inform you that the Board of Directors of the Company at their meeting held today, i.e. January 31, 2023, approved the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2022 along with the Limited Review Report thereon. CHEMO PHARMA LABORATORIES LTD. - 506365 - Board Meeting Intimation for Approval Of The Un-Audited Financial Statement For The Quarter And Nine Months Ended December 31, 2022 Along With The Limited Review Report.
CHEMO PHARMA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, January 31, 2023 at 04:00 p.m. at the Corporate Office of the Company, inter alia, to consider and approve the Un-Audited Financial Statement for the quarter and nine months ended December 31, 2022 along with the Limited Review Report.